Blinatumomab Biosimilar – Anti-CD19/CD3E Bispecific Antibody

Blinatumomab (Blincyto, Amgen), a bi-specific antibody, is a first-in-class, targeted immunotherapy agent for treatment of B-cell malignancies with a novel mechanism of action which involves in-vivo engagement of the patient’s T cells with CD19-expressing tumour cells. The name is derived from the term B lineage-specific anti-tumour mouse monoclonal antibody. Blinatumomab is a fusion protein composed of two single-chain antibodies (scFvs) with a short non-immunogenic linker sequence of 5 amino acids used to recombinantly link the two scFvs in tandem. The V light-chain (VL) and V heavy-chain (VH) domains of the antibodies are cloned from anti-CD19 HD37 and anti-CD3 TR66 murine hybridomas. The construct is expressed in Chinese hamster ovary cells and purified by its histidine tail. Clinical trials have demonstrated its efficacy in relapsed B-cell Acute Lymphoblastic Leukaemia (B-ALL) and B-cell Non-Hodgkin’s Lymphoma including in patients who are refractory to chemotherapy.

Product Details
Species Reactivity	Human
Source	Mammalian cells
Host/Isotype	(scFv-kappa-heavy)-(scFv-heavy-kappa); His-Tag
Class	Bispecific Antibody
Type	Recombinant Humanized
Conjugate	Unconjugated
Molecular Weight	54.1kDa
Storage Condition	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws
Storage Buffer	PBS buffer PH7.5